Posted in | News | Humanoids

Rainbow Robotics Set to Make a Splash in the U.S. Market With Its Innovative Cobots

Rainbow Robotics, the South Korean Company renowned for developing HUBO, the first bipedal humanoid robot and winner of the prestigious DARPA Robotics Challenge (DRC), is set to make a splash in the U.S. market with its innovative line of six-axis collaborative robots, or cobots.

After showcasing its RB-series cobots at Automate 2022 in Detroit, Rainbow Robotics has partnered with Cascara Robotics for distribution throughout North America. Bryan Peel, the founder of Cascara Robotics, expressed his enthusiasm for the partnership, saying, "We are thrilled to bring Rainbow Robotics to the United States. With the increased need for automation, it is exciting to partner with such an innovative company."

The RB line features five models: RB3-730, RB3-1200, RB5-850, RB10-1300, and RB16-900. Three additional models—RB1-500, RB20-1700, and RB25-2000—will be released later this year.

The RB-series cobots are designed for precision, speed, and compatibility with various industrial applications. Crafted from aluminum and steel, these robots run on a Linux-based operating system and feature advanced collision detection and gravity-compensation systems. As a result, they are suitable for a wide range of applications, including CNC machine tending and demolding of parts, with repeatability within 0.1 mm.

Rainbow Robotics utilizes in-house manufacturing for nearly every component of their RB-series COBOT. As a result, RB-series provides an attractive alternative to other OEM models with a higher quality standard and a price up to 30 percent lower than comparable products. As the Company expands into the U.S. market, its advanced robotics solutions promise to revolutionize the industry.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.